請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/72935
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 嚴震東 | |
dc.contributor.author | Wen-Ying Lin | en |
dc.contributor.author | 林文瑛 | zh_TW |
dc.date.accessioned | 2021-06-17T07:10:54Z | - |
dc.date.available | 2019-07-25 | |
dc.date.copyright | 2019-07-25 | |
dc.date.issued | 2019 | |
dc.date.submitted | 2019-07-19 | |
dc.identifier.citation | Reference
1. Williams AC, Craig KD. Updating the definition of pain. Pain. 2016;157(11):2420-2423. 2. Devor M. Neuropathic pain. In: McMahon SB, ed. Textbook of pain 6ed. PA: Elsevier; 2013:861. 3. Kennedy JD. Neuropathic pain: molecular complexity underlies continuing unmet medical need. J Med Chem. 2007;50(11):2547-2556. 4. Mantyh P. Cancer pain. In: McMahon SB, ed. Textbook of pain. 6 ed. PA: Elsevier; 2013:1029. 5. Thompson SJ, Bushnell MC. Rodent functional and anatomical imaging of pain. Neurosci Lett. 2012;520(2):131-139. 6. Boellaard R, Delgado-Bolton R, Oyen WJ, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42(2):328-354. 7. Egloff N, Sabbioni ME, Salathe C, Wiest R, Juengling FD. Nondermatomal somatosensory deficits in patients with chronic pain disorder: clinical findings and hypometabolic pattern in FDG-PET. Pain. 2009;145(1-2):252-258. 8. Buvanendran A, Ali A, Stoub TR, Kroin JS, Tuman KJ. Brain activity associated with chronic cancer pain. Pain Physician. 2010;13(5):E337-342. 9. Kim CE, Kim YK, Chung G, et al. Identifying neuropathic pain using (18)F-FDG micro-PET: a multivariate pattern analysis. Neuroimage. 2014;86:311-316. 10. Thompson SJ, Millecamps M, Aliaga A, et al. Metabolic brain activity suggestive of persistent pain in a rat model of neuropathic pain. Neuroimage. 2014;91:344-352. 11. Apkarian AV, Bushnell MC, Treede RD, Zubieta JK. Human brain mechanisms of pain perception and regulation in health and disease. Eur J Pain. 2005;9(4):463-484. 12. Schweinhardt P, Bushnell MC. Pain imaging in health and disease--how far have we come? J Clin Invest. 2010;120(11):3788-3797. 13. Davis KD, Seminowicz DA. Insights for Clinicians From Brain Imaging Studies of Pain. Clin J Pain. 2017;33(4):291-294. 14. Malfliet A, Coppieters I, Van Wilgen P, et al. Brain changes associated with cognitive and emotional factors in chronic pain: A systematic review. Eur J Pain. 2017;21(5):769-786. 15. Gilron I, Jensen TS, Dickenson AH. Combination pharmacotherapy for management of chronic pain: from bench to bedside. The Lancet Neurology. 2013;12(11):1084-1095. 16. Holbech JV, Jung A, Jonsson T, Wanning M, Bredahl C, Bach FW. Combination treatment of neuropathic pain: Danish expert recommendations based on a Delphi process. J Pain Res. 2017;10:1467-1475. 17. Baron R. Mechanisms of disease: neuropathic pain--a clinical perspective. Nat Clin Pract Neurol. 2006;2(2):95-106. 18. Woolf CJ. The pathophysiology of peripheral neuropathic pain--abnormal peripheral input and abnormal central processing. Acta Neurochir Suppl (Wien). 1993;58:125-130. 19. Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. The Lancet Neurology. 2015;14(2):162-173. 20. Vo T, Rice AS, Dworkin RH. Non-steroidal anti-inflammatory drugs for neuropathic pain: how do we explain continued widespread use? Pain. 2009;143(3):169-171. 21. Rooks WH, 2nd. The pharmacologic activity of ketorolac tromethamine. Pharmacotherapy. 1990;10(6 ( Pt 2)):30S-32S. 22. McNicol ED, Midbari A, Eisenberg E. Opioids for neuropathic pain. Cochrane Database Syst Rev. 2013(8):CD006146. 23. Bauer CS, Nieto-Rostro M, Rahman W, et al. The increased trafficking of the calcium channel subunit alpha2delta-1 to presynaptic terminals in neuropathic pain is inhibited by the alpha2delta ligand pregabalin. J Neurosci. 2009;29(13):4076-4088. 24. Lopez-Munoz FJ, Diaz-Reval MI, Terron JA, Deciga-Campos M. Analysis of the analgesic interactions between ketorolac and tramadol during arthritic nociception in rat. Eur J Pharmacol. 2004;484(2-3):157-165. 25. Narai Y, Imamachi N, Saito Y. Gabapentin augments the antihyperalgesic effects of diclofenac sodium through spinal action in a rat postoperative pain model. Anesth Analg. 2012;115(1):189-193. 26. Shinozaki T, Yamada T, Nonaka T, Yamamoto T. Acetaminophen and non-steroidal anti-inflammatory drugs interact with morphine and tramadol analgesia for the treatment of neuropathic pain in rats. J Anesth. 2015;29(3):386-395. 27. Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17(9):1113-e1188. 28. Decosterd I, Woolf CJ. Spared nerve injury: an animal model of persistent peripheral neuropathic pain. Pain. 2000;87(2):149-158. 29. Erichsen HK, Hao JX, Xu XJ, Blackburn-Munro G. Comparative actions of the opioid analgesics morphine, methadone and codeine in rat models of peripheral and central neuropathic pain. Pain. 2005;116(3):347-358. 30. Kim JS, Kroin JS, Li X, et al. The rat intervertebral disk degeneration pain model: relationships between biological and structural alterations and pain. Arthritis Res Ther. 2011;13(5):R165. 31. Lee KS, Huang YH, Yen CT. Periaqueductal gray stimulation suppresses spontaneous pain behavior in rats. Neurosci Lett. 2012;514(1):42-45. 32. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods. 1994;53(1):55-63. 33. Choi Y, Yoon YW, Na HS, Kim SH, Chung JM. Behavioral signs of ongoing pain and cold allodynia in a rat model of neuropathic pain. Pain. 1994;59(3):369-376. 34. Romano CL, Romano D, Bonora C, Mineo G. Pregabalin, celecoxib, and their combination for treatment of chronic low-back pain. J Orthop Traumatol. 2009;10(4):185-191. 35. Espinosa-Juarez JV, Jaramillo-Morales OA, Corona-Ramos JN, Medina-Lopez JR, Lopez-Munoz FJ. Antinociceptive Interactions Between Meloxicam and Gabapentin in Neuropathic Pain Depend on the Ratio used in Combination in Rats. Drug Dev Res. 2016;77(3):134-142. 36. Abass M, Mosbah E, Rizk A, Karrouf G, Zaghloul A. Synergistic efficacy of tramadol and meloxicam on alleviation of pain and selected immunological variables after sciatic nerve ligation in rats. International Journal of Veterinary Science and Medicine. 2014;2(1):14-20. 37. Warner TD, Mitchell JA. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J. 2004;18(7):790-804. 38. Djouhri L, Koutsikou S, Fang X, McMullan S, Lawson SN. Spontaneous pain, both neuropathic and inflammatory, is related to frequency of spontaneous firing in intact C-fiber nociceptors. J Neurosci. 2006;26(4):1281-1292. 39. Smith T, Al Otaibi M, Sathish J, Djouhri L. Increased expression of HCN2 channel protein in L4 dorsal root ganglion neurons following axotomy of L5- and inflammation of L4-spinal nerves in rats. Neuroscience. 2015;295:90-102. 40. Vaughan CW, Ingram SL, Connor MA, Christie MJ. How opioids inhibit GABA-mediated neurotransmission. Nature. 1997;390(6660):611-614. 41. Shimoyama M, Shimoyama N, Hori Y. Gabapentin affects glutamatergic excitatory neurotransmission in the rat dorsal horn. Pain. 2000;85(3):405-414. 42. Baba H, Kohno T, Moore KA, Woolf CJ. Direct activation of rat spinal dorsal horn neurons by prostaglandin E2. J Neurosci. 2001;21(5):1750-1756. 43. Hurley RW, Chatterjea D, Rose Feng M, Taylor CP, Hammond DL. Gabapentin and pregabalin can interact synergistically with naproxen to produce antihyperalgesia. Anesthesiology. 2002;97(5):1263-1273. 44. Reimer M, Helfert SM, Baron R. Phenotyping neuropathic pain patients: implications for individual therapy and clinical trials. Curr Opin Support Palliat Care. 2014;8(2):124-129. 45. Baron R, Förster M, Binder A. Subgrouping of patients with neuropathic pain according to pain-related sensory abnormalities: a first step to a stratified treatment approach. The Lancet Neurology. 2012;11(11):999-1005. 46. Baron R, Maier C, Attal N, et al. Peripheral neuropathic pain: a mechanism-related organizing principle based on sensory profiles. Pain. 2017;158(2):261-272. 47. Hung CH, Wang JC, Strichartz GR. Spontaneous Chronic Pain After Experimental Thoracotomy Revealed by Conditioned Place Preference: Morphine Differentiates Tactile Evoked Pain From Spontaneous Pain. J Pain. 2015;16(9):903-912. 48. Han DW, Kweon TD, Lee JS, Lee YW. Antiallodynic effect of pregabalin in rat models of sympathetically maintained and sympathetic independent neuropathic pain. Yonsei Med J. 2007;48(1):41-47. 49. Apaydin S, Uyar M, Karabay NU, Erhan E, Yegul I, Tuglular I. The antinociceptive effect of tramadol on a model of neuropathic pain in rats. Life Sci. 2000;66(17):1627-1637. 50. Lin FS, Shyu BC, Shieh JY, Sun WZ. Nitrous oxide suppresses tonic and phasic nociceptive behaviors but not formalin-induced c-Fos expression in the rat spinal cord dorsal horn. Acta Anaesthesiol Sin. 2003;41(3):115-123. 51. Wen YR, Suter MR, Ji RR, et al. Activation of p38 mitogen-activated protein kinase in spinal microglia contributes to incision-induced mechanical allodynia. Anesthesiology. 2009;110(1):155-165. 52. Jensen TS, Baron R, Haanpaa M, et al. A new definition of neuropathic pain. Pain. 2011;152(10):2204-2205. 53. Treede RD, Jensen TS, Campbell JN, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology. 2008;70(18):1630-1635. 54. Truini A, Garcia-Larrea L, Cruccu G. Reappraising neuropathic pain in humans--how symptoms help disclose mechanisms. Nat Rev Neurol. 2013;9(10):572-582. 55. Patel R, Dickenson AH. Neuronal hyperexcitability in the ventral posterior thalamus of neuropathic rats: modality selective effects of pregabalin. J Neurophysiol. 2016;116(1):159-170. 56. Becerra L, Morris S, Bazes S, et al. Trigeminal neuropathic pain alters responses in CNS circuits to mechanical (brush) and thermal (cold and heat) stimuli. J Neurosci. 2006;26(42):10646-10657. 57. Kupers R, Lonsdale MN, Aasvang E, Kehlet H. A positron emission tomography study of wind-up pain in chronic postherniotomy pain. Eur J Pain. 2011;15(7):698 e691-616. 58. Kupers R. Functional imaging of allodynia in complex regional pain syndrome. Neurology. 2006;67(8):1526; author reply 1526. 59. Moisset X, Villain N, Ducreux D, et al. Functional brain imaging of trigeminal neuralgia. Eur J Pain. 2011;15(2):124-131. 60. Peyron R, Faillenot I, Pomares FB, Le Bars D, Garcia-Larrea L, Laurent B. Mechanical allodynia in neuropathic pain. Where are the brain representations located? A positron emission tomography (PET) study. Eur J Pain. 2013;17(9):1327-1337. 61. Cauda F, D'Agata F, Sacco K, et al. Altered resting state attentional networks in diabetic neuropathic pain. J Neurol Neurosurg Psychiatry. 2010;81(7):806-811. 62. Cauda F, Sacco K, Duca S, et al. Altered resting state in diabetic neuropathic pain. PLoS One. 2009;4(2):e4542. 63. Hsieh JC, Belfrage M, Stone-Elander S, Hansson P, Ingvar M. Central representation of chronic ongoing neuropathic pain studied by positron emission tomography. Pain. 1995;63(2):225-236. 64. Lin HC, Huang YH, Chao TH, Lin WY, Sun WZ, Yen CT. Gabapentin reverses central hypersensitivity and suppresses medial prefrontal cortical glucose metabolism in rats with neuropathic pain. Mol Pain. 2014;10:63. 65. Ono Y, Lin HC, Tzen KY, et al. Active coping with stress suppresses glucose metabolism in the rat hypothalamus. Stress. 2012;15(2):207-217. 66. Devonshire IM, Burston JJ, Xu L, et al. Manganese-enhanced magnetic resonance imaging depicts brain activity in models of acute and chronic pain: A new window to study experimental spontaneous pain? Neuroimage. 2017;157:500-510. 67. Witting N, Kupers RC, Svensson P, Jensen TS. A PET activation study of brush-evoked allodynia in patients with nerve injury pain. Pain. 2006;120(1-2):145-154. 68. Treede RD, Kenshalo DR, Gracely RH, Jones AK. The cortical representation of pain. Pain. 1999;79(2-3):105-111. 69. Ab Aziz CB, Ahmad AH. The role of the thalamus in modulating pain. Malays J Med Sci. 2006;13(2):11-18. 70. Moulton EA, Schmahmann JD, Becerra L, Borsook D. The cerebellum and pain: passive integrator or active participator? Brain Res Rev. 2010;65(1):14-27. 71. Borsook D, Moulton EA, Pendse G, et al. Comparison of evoked vs. spontaneous tics in a patient with trigeminal neuralgia (tic doloureux). Mol Pain. 2007;3:34. 72. Spisak T, Pozsgay Z, Aranyi C, et al. Central sensitization-related changes of effective and functional connectivity in the rat inflammatory trigeminal pain model. Neuroscience. 2017;344:133-147. 73. Hunter JC, Gogas KR, Hedley LR, et al. The effect of novel anti-epileptic drugs in rat experimental models of acute and chronic pain. Eur J Pharmacol. 1997;324(2-3):153-160. 74. Christoph T, De Vry J, Schiene K, Tallarida RJ, Tzschentke TM. Synergistic antihypersensitive effects of pregabalin and tapentadol in a rat model of neuropathic pain. Eur J Pharmacol. 2011;666(1-3):72-79. 75. Wang RR, Lou GD, Yu J, et al. Oral Administration of Pregabalin in Rats before or after Nerve Injury Partially Prevents Spontaneous Neuropathic Pain and Long Outlasts the Treatment Period. Pharmacology. 2016;97(5-6):251-258. 76. Cao Y, Wang H, Chiang CY, Dostrovsky JO, Sessle BJ. Pregabalin suppresses nociceptive behavior and central sensitization in a rat trigeminal neuropathic pain model. J Pain. 2013;14(2):193-204. 77. Murai N, Sekizawa T, Gotoh T, et al. Spontaneous and evoked pain-associated behaviors in a rat model of neuropathic pain respond differently to drugs with different mechanisms of action. Pharmacol Biochem Behav. 2016;141:10-17. 78. Miyazaki R, Yamamoto T. The efficacy of morphine, pregabalin, gabapentin, and duloxetine on mechanical allodynia is different from that on neuroma pain in the rat neuropathic pain model. Anesth Analg. 2012;115(1):182-188. 79. Ding L, Cai J, Guo XY, Meng XL, Xing GG. The antiallodynic action of pregabalin may depend on the suppression of spinal neuronal hyperexcitability in rats with spared nerve injury. Pain Res Manag. 2014;19(4):205-211. 80. Gusnard DA, Akbudak E, Shulman GL, Raichle ME. Medial prefrontal cortex and self-referential mental activity: relation to a default mode of brain function. Proc Natl Acad Sci U S A. 2001;98(7):4259-4264. 81. Phelps EA, Delgado MR, Nearing KI, LeDoux JE. Extinction learning in humans: role of the amygdala and vmPFC. Neuron. 2004;43(6):897-905. 82. Metz AE, Yau HJ, Centeno MV, Apkarian AV, Martina M. Morphological and functional reorganization of rat medial prefrontal cortex in neuropathic pain. Proc Natl Acad Sci U S A. 2009;106(7):2423-2428. 83. LeBlanc BW, Bowary PM, Chao YC, Lii TR, Saab CY. Electroencephalographic signatures of pain and analgesia in rats. Pain. 2016;157(10):2330-2340. 84. Behbehani MM. Functional characteristics of the midbrain periaqueductal gray. Prog Neurobiol. 1995;46(6):575-605. 85. Thompson JM, Neugebauer V. Amygdala Plasticity and Pain. Pain Res Manag. 2017;2017:8296501. 86. Li Z, Taylor CP, Weber M, et al. Pregabalin is a potent and selective ligand for alpha(2)delta-1 and alpha(2)delta-2 calcium channel subunits. Eur J Pharmacol. 2011;667(1-3):80-90. 87. Cain SM, Bohnet B, LeDue J, et al. In vivo imaging reveals that pregabalin inhibits cortical spreading depression and propagation to subcortical brain structures. Proc Natl Acad Sci U S A. 2017;114(9):2401-2406. 88. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006;12(20 Pt 2):6243s-6249s. 89. Irvin W, Jr., Muss HB, Mayer DK. Symptom management in metastatic breast cancer. Oncologist. 2011;16(9):1203-1214. 90. Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004;350(16):1655-1664. 91. Roca H, McCauley LK. Inflammation and skeletal metastasis. Bonekey Rep. 2015;4:706. 92. Apkarian AV, Hashmi JA, Baliki MN. Pain and the brain: specificity and plasticity of the brain in clinical chronic pain. Pain. 2011;152(3 Suppl):S49-64. 93. Watkins LR, Maier SF. The pain of being sick: implications of immune-to-brain communication for understanding pain. Annu Rev Psychol. 2000;51:29-57. 94. Capuron L, Miller AH. Immune system to brain signaling: neuropsychopharmacological implications. Pharmacol Ther. 2011;130(2):226-238. 95. Honore P, Rogers SD, Schwei MJ, et al. Murine models of inflammatory, neuropathic and cancer pain each generates a unique set of neurochemical changes in the spinal cord and sensory neurons. Neuroscience. 2000;98(3):585-598. 96. Sabino MA, Luger NM, Mach DB, Rogers SD, Schwei MJ, Mantyh PW. Different tumors in bone each give rise to a distinct pattern of skeletal destruction, bone cancer-related pain behaviors and neurochemical changes in the central nervous system. Int J Cancer. 2003;104(5):550-558. 97. Ripamonti CI, Santini D, Maranzano E, Berti M, Roila F, Group EGW. Management of cancer pain: ESMO Clinical Practice Guidelines. Ann Oncol. 2012;23 Suppl 7:vii139-154. 98. Swarm RA, Abernethy AP, Anghelescu DL, et al. Adult cancer pain. J Natl Compr Canc Netw. 2013;11(8):992-1022. 99. Kim J, Ham S, Hong H, Moon C, Im HI. Brain Reward Circuits in Morphine Addiction. Mol Cells. 2016;39(9):645-653. 100. Kupers R, Kehlet H. Brain imaging of clinical pain states: a critical review and strategies for future studies. Lancet Neurol. 2006;5(12):1033-1044. 101. Hansen RR, Nielsen CK, Nasser A, et al. P2X7 receptor-deficient mice are susceptible to bone cancer pain. Pain. 2011;152(8):1766-1776. 102. Jimenez-Andrade JM, Mantyh WG, Bloom AP, Ferng AS, Geffre CP, Mantyh PW. Bone cancer pain. Ann N Y Acad Sci. 2010;1198:173-181. 103. Morrow TJ, Paulson PE, Danneman PJ, Casey KL. Regional changes in forebrain activation during the early and late phase of formalin nociception: analysis using cerebral blood flow in the rat. Pain. 1998;75(2-3):355-365. 104. Kakonen SM, Selander KS, Chirgwin JM, et al. Transforming growth factor-beta stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways. J Biol Chem. 2002;277(27):24571-24578. 105. McCaffrey G, Thompson ML, Majuta L, et al. NGF blockade at early times during bone cancer development attenuates bone destruction and increases limb use. Cancer Res. 2014;74(23):7014-7023. 106. Clohisy DR, Mantyh PW. Bone cancer pain. Cancer. 2003;97(3 Suppl):866-873. 107. Mediati RD, Vellucci R, Dodaro L. Pathogenesis and clinical aspects of pain in patients with osteoporosis. Clin Cases Miner Bone Metab. 2014;11(3):169-172. 108. Remeniuk B, King T, Sukhtankar D, et al. Disease modifying actions of interleukin-6 blockade in a rat model of bone cancer pain. Pain. 2018;159(4):684-698. 109. Hopkins SJ. Central nervous system recognition of peripheral inflammation: a neural, hormonal collaboration. Acta Biomed. 2007;78 Suppl 1:231-247. 110. Tizard I. Sickness behavior, its mechanisms and significance. Anim Health Res Rev. 2008;9(1):87-99. 111. Buehlmann D, Grandjean J, Xandry J, Rudin M. Longitudinal resting-state functional magnetic resonance imaging in a mouse model of metastatic bone cancer reveals distinct functional reorganizations along a developing chronic pain state. Pain. 2018;159(4):719-727. 112. Reis GM, Dias QM, Silveira JW, Del Vecchio F, Garcia-Cairasco N, Prado WA. Antinociceptive effect of stimulating the occipital or retrosplenial cortex in rats. J Pain. 2010;11(10):1015-1026. 113. Chiou CS, Chen CC, Tsai TC, Huang CC, Chou D, Hsu KS. Alleviating Bone Cancer-induced Mechanical Hypersensitivity by Inhibiting Neuronal Activity in the Anterior Cingulate Cortex. Anesthesiology. 2016;125(4):779-792. 114. Hooker BA, Tobon G, Baker SJ, et al. Gabapentin-induced pharmacodynamic effects in the spinal nerve ligation model of neuropathic pain. Eur J Pain. 2014;18(2):223-237. 115. Pfeiffer A, Pasi A, Mehraein P, Herz A. Opiate receptor binding sites in human brain. Brain Res. 1982;248(1):87-96. 116. Cross AJ, Hille C, Slater P. Subtraction autoradiography of opiate receptor subtypes in human brain. Brain Res. 1987;418(2):343-348. 117. Pilapil C, Welner S, Magnan J, Gauthier S, Quirion R. Autoradiographic distribution of multiple classes of opioid receptor binding sites in human forebrain. Brain Res Bull. 1987;19(5):611-615. 118. Baumgartner U, Buchholz HG, Bellosevich A, et al. High opiate receptor binding potential in the human lateral pain system. Neuroimage. 2006;30(3):692-699. 119. Neugebauer V. Amygdala pain mechanisms. Handb Exp Pharmacol. 2015;227:261-284. 120. Pertovaara A, Wei H, Hamalainen MM. Lidocaine in the rostroventromedial medulla and the periaqueductal gray attenuates allodynia in neuropathic rats. Neurosci Lett. 1996;218(2):127-130. 121. Suzuki R, Rahman W, Hunt SP, Dickenson AH. Descending facilitatory control of mechanically evoked responses is enhanced in deep dorsal horn neurones following peripheral nerve injury. Brain Res. 2004;1019(1-2):68-76. 122. Huang ZX, Lu ZJ, Ma WQ, et al. Involvement of RVM-expressed P2X7 receptor in bone cancer pain: mechanism of descending facilitation. Pain. 2014;155(4):783-791. 123. Lee MC, Wanigasekera V, Tracey I. Imaging opioid analgesia in the human brain and its potential relevance for understanding opioid use in chronic pain. Neuropharmacology. 2014;84:123-130. 124. Becerra L, Harter K, Gonzalez RG, Borsook D. Functional magnetic resonance imaging measures of the effects of morphine on central nervous system circuitry in opioid-naive healthy volunteers. Anesth Analg. 2006;103(1):208-216, table of contents. 125. Luger NM, Sabino MA, Schwei MJ, et al. Efficacy of systemic morphine suggests a fundamental difference in the mechanisms that generate bone cancer vs inflammatory pain. Pain. 2002;99(3):397-406. 126. Maeda L, Ono M, Koyama T, et al. Human brain activity associated with painful mechanical stimulation to muscle and bone. J Anesth. 2011;25(4):523-530. 127. Baliki MN, Geha PY, Jabakhanji R, Harden N, Schnitzer TJ, Apkarian AV. A preliminary fMRI study of analgesic treatment in chronic back pain and knee osteoarthritis. Mol Pain. 2008;4:47. 128. Kulkarni B, Bentley DE, Elliott R, et al. Arthritic pain is processed in brain areas concerned with emotions and fear. Arthritis Rheum. 2007;56(4):1345-1354. 129. Gwilym SE, Keltner JR, Warnaby CE, et al. Psychophysical and functional imaging evidence supporting the presence of central sensitization in a cohort of osteoarthritis patients. Arthritis Rheum. 2009;61(9):1226-1234. 130. Gustin SM, Peck CC, Wilcox SL, Nash PG, Murray GM, Henderson LA. Different pain, different brain: thalamic anatomy in neuropathic and non-neuropathic chronic pain syndromes. J Neurosci. 2011;31(16):5956-5964. 131. Schmidt-Wilcke T, Leinisch E, Ganssbauer S, et al. Affective components and intensity of pain correlate with structural differences in gray matter in chronic back pain patients. Pain. 2006;125(1-2):89-97. 132. Vachon-Presseau E. Effects of stress on the corticolimbic system: implications for chronic pain. Prog Neuropsychopharmacol Biol Psychiatry. 2018;87(Pt B):216-223. 133. Baliki MN, Chialvo DR, Geha PY, et al. Chronic pain and the emotional brain: specific brain activity associated with spontaneous fluctuations of intensity of chronic back pain. J Neurosci. 2006;26(47):12165-12173. 134. Hashmi JA, Baliki MN, Huang L, et al. Shape shifting pain: chronification of back pain shifts brain representation from nociceptive to emotional circuits. Brain. 2013;136(Pt 9):2751-2768. 135. Cronin KA, Lake AJ, Scott S, et al. Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics. Cancer. 2018;124(13):2785-2800. 136. Bouhassira D, Luporsi E, Krakowski I. Prevalence and incidence of chronic pain with or without neuropathic characteristics in patients with cancer. Pain. 2017;158(6):1118-1125. 137. Barbas H, Zikopoulos B. The prefrontal cortex and flexible behavior. Neuroscientist. 2007;13(5):532-545. 138. Berkowitz RL, Coplan JD, Reddy DP, Gorman JM. The human dimension: how the prefrontal cortex modulates the subcortical fear response. Rev Neurosci. 2007;18(3-4):191-207. 139. Lorenz J, Minoshima S, Casey KL. Keeping pain out of mind: the role of the dorsolateral prefrontal cortex in pain modulation. Brain. 2003;126(Pt 5):1079-1091. 140. Schoenbaum G, Takahashi Y, Liu TL, McDannald MA. Does the orbitofrontal cortex signal value? Ann N Y Acad Sci. 2011;1239:87-99. 141. Winston JS, Vlaev I, Seymour B, Chater N, Dolan RJ. Relative valuation of pain in human orbitofrontal cortex. J Neurosci. 2014;34(44):14526-14535. 142. Nieuwenhuys R. The insular cortex: a review. Prog Brain Res. 2012;195:123-163. 143. Davis KD, Flor H, Greely HT, et al. Brain imaging tests for chronic pain: medical, legal and ethical issues and recommendations. Nat Rev Neurol. 2017;13(10):624-638. 144. Ghaziri J, Tucholka A, Girard G, et al. Subcortical structural connectivity of insular subregions. Sci Rep. 2018;8(1):8596. 145. Gogolla N. The insular cortex. Curr Biol. 2017;27(12):R580-R586. 146. Shura RD, Hurley RA, Taber KH. Insular cortex: structural and functional neuroanatomy. J Neuropsychiatry Clin Neurosci. 2014;26(4):276-282. 147. Kraynak TE, Marsland AL, Wager TD, Gianaros PJ. Functional neuroanatomy of peripheral inflammatory physiology: A meta-analysis of human neuroimaging studies. Neurosci Biobehav Rev. 2018;94:76-92. 148. Wager TD, Atlas LY. The neuroscience of placebo effects: connecting context, learning and health. Nat Rev Neurosci. 2015;16(7):403-418. 149. Bannister K, Qu C, Navratilova E, et al. Multiple sites and actions of gabapentin-induced relief of ongoing experimental neuropathic pain. Pain. 2017;158(12):2386-2395. 150. Deitos A, Soldatelli MD, Dussan-Sarria JA, et al. Novel Insights of Effects of Pregabalin on Neural Mechanisms of Intracortical Disinhibition in Physiopathology of Fibromyalgia: An Explanatory, Randomized, Double-Blind Crossover Study. Front Hum Neurosci. 2018;12:406. 151. Firestone LL, Gyulai F, Mintun M, Adler LJ, Urso K, Winter PM. Human brain activity response to fentanyl imaged by positron emission tomography. Anesth Analg. 1996;82(6):1247-1251. 152. Takasu K, Ogawa K, Nakamura A, et al. Enhanced GABAergic synaptic transmission at VLPAG neurons and potent modulation by oxycodone in a bone cancer pain model. Br J Pharmacol. 2015;172(8):2148-2164. 153. Davis KD. Imaging vs quantitative sensory testing to predict chronic pain treatment outcomes. Pain. 2019;160 Suppl 1:S59-S65. 154. Rogachov A, Bhatia A, Cheng JC, et al. Plasticity in the dynamic pain connectome associated with ketamine-induced neuropathic pain relief. Pain. 2019;160(7):1670-1679. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/72935 | - |
dc.description.abstract | 疼痛警告人類和動物避免受到危險和傷害,疼痛也會保護我們,直到受傷的組織癒合。然而,疼痛是一種令人不快的感覺和情緒體驗。儘管之前許多研究已使用功能性腦部影像來解釋疼痛的腦部模型,在疼痛感知的大腦特徵中,存在一些不一致的結果,仍然沒有解答。
本論文的目的是提供腦部處理的疼痛感知和止痛線索。第一部分是觀察大鼠在不同的神經性疼痛行為和治療的反應。在第二部分研究中,我們使用正子射影斷層掃描影像,鑑定了神經性疼痛大鼠在兩種不同的神經性疼痛行為中的腦部活化區域。此外,我們測試了pregabalin 的治療在腦部中之反應。在第三部分的研究中,我們確定了癌症疼痛小鼠和嗎啡止痛的腦部活化區域。最後,我們利用回顧性研究分析了癌症疼痛患者的正子射影斷層掃描影像中大腦部分。在這些人類和囓齒動物的研究中,我們發現一個持續活動的大腦區域-腦島皮質。我們提出,腦島皮質可能是人類和大鼠最重要的疼痛相關的區域。 | zh_TW |
dc.description.abstract | Pain alerts humans and animals from danger and injury, also it protects us until the injured tissue heal. However, pain is an unpleasant sensory and emotional experience. Although numerous studies have been performed to delineate pain mechanism using functional brain imaging, there were still some discrepant results in the brain signature for pain has not been solved.
The purpose of this dissertation is to provide the clue of brain processing in pain perception and analgesia using FDG-PET imaging. The first part is observing different neuropathic pain behaviors and treatment response in rats. In the second series of studies, we used FDG-PET to identify the activated brain areas of neuropathic pain rats in different neuropathic pain behaviors. Furthermore, we tested the treatment response of these brain areas to pregabalin. In the third study, we identified the activated brain area in cancer pain mice and morphine analgesia. Finally, we retrospectively analyzed brain FDG-PET in cancer pain patients. In these human and rodent studies, we found one consistently activated brain area-i.e., the insular cortex. We propose that insular cortex maybe one of the most important pain related areas in both human and rodents. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T07:10:54Z (GMT). No. of bitstreams: 1 ntu-108-D01b41004-1.pdf: 13397454 bytes, checksum: cfc6ea5a47ccc285d9428b8ee9ae8b39 (MD5) Previous issue date: 2019 | en |
dc.description.tableofcontents | 口試委員會審定書…………………….……………..……………………….…#
誌謝…………………………………………………………..….………………i 中文摘要……………………………………………………………………………ii Abstract…………………………………………………………...………………...iii Contents……………………………………………………………………………..iv List of figures………………………………………………………………………..ix List of tables……………………………………………………….……………..…..x Chapter 1: Background………………………………………….…………………..1 1.1 The definition of pain………………………………….….…..…………1 1.1.1 Classification of pain……………………………...…..………1 1.1.2 Cancer pain…………………………..……...………………..2 1.2 Functional brain imaging for study pain: positron emission tomography..2 1.3 Brain regions involved in the experience of pain………………...……...3 1.4 Motivation and purpose: Initiated from a failed clinical trial…….…….5 Chapter 2: Synergistic symptom-specific effects of ketorolac-tramadol and ketorolac-pregabalin in a rat model of peripheral neuropathy…..….…9 2.1 Introduction……………………………………………..…….………..9 2.2 Materials and Methods…………………………………..………….….10 2.2.1 Animals…………..……………………………….…..……….10 2.2.2 Sciatic nerve injury surgery…………………………….…….11 2.2.3 Drugs……………………………………………..………….11 2.2.4 Behavioral test and drug injection………………………...….12 2.2.5 Data analysis and statistics……………………………...……14 2.3 Results……………….……………………….………………………..14 2.3.1 Effect of tramadol, ketorolac and pregabalin…………..………14 2.3.2 Effect of combination ketorolac and tramadol or pregabalin…15 2.4 Discussion…………………………………….…….…………………20 Chapter 3: FDG-PET imaging of spontaneous and evoked pain in a rat model of peripheral neuropathic pain…………………………………………..26 3.1 Introduction…………………….………….………………….……….26 3.2 Materials and method..……....……………….………………..………..28 3.2.1 Animals……………………..……………...………….………28 3.2.2 SNI surgery…………...…………………………….………..29 3.2.3 Behavior tests and drug injection……………...……….…….29 3.2.4 PET images processing…………...……………….…………31 3.2.5 Connectivity analysis…...……………………………………34 3.2.6 Data analysis…………………...…………………………….35 3.3 Results…………………………….….………………………………..36 3.3.1 Neuropathic behavior were alleviated by pregabalin………….36 3.3.2 Brain glucose metabolism mapping in two groups……………37 3.3.3 Functional connectivity of the brain regions in two groups….38 3.4 Discussion……………………………….………………….…………41 Chapter 4: Longitudinal FDG-PET scan study of brain changes in mice with cancer induced bone pain and after morphine analgesia……………46 4.1 Introduction………………….…………………………….………….46 4.2 Materials and method…………………………………….….….………47 4.2.1 Animals……………………..……………….…….………...47 4.2.2 Cell lines…………...………………………….…….……….48 4.2.3 Bone cancer operation………………...……………….………48 4.2.4 Drug…………………………………...….……….….……...49 4.2.5 Behavioral tests……………………………….…….……….49 4.2.6 FDG-PET scan protocol……...…………………..….………50 4.2.7 PET image processing…………..…………………..….……51 4.2.8 Statistical mapping of PET images……..……………………52 4.2.9 Histopathological examination………...…………………….54 4.2.10 Statistical analysis………………..……………..…………...54 4.3 Results………………………………………………………………..54 4.3.1 CIBP mice showed limb use deficits with mechanical and cold allodynia…………………………………………………….…54 4.3.2 Morphine alleviated CIBP………………..………………….55 4.3.3 Brain glucose metabolic activity changes in CIBP and under morphine analgesia……………….…………………………...57 4.3.4 Regions of interest (ROI) analysis of specific brain area…….59 4.3.5 Cancer-induced histopathological changes in the femur..….61 4.4 Discussion………………………………………………….…….……62 Chapter 5: Brain changes of FDG PET/CT in patient with cancer pain: A clinical retrospective study………………………………..……………………69 5.1 Introduction…………………………………………….…...…………69 5.2 Materials and method………………………………………………….70 5.2.1 Study design and subjects……………………..……………….70 5.2.2 FDG PET/CT imaging……………...………………………..70 5.2.3 PET imaging processing………..……………………………71 5.3 Result………………………………………………………………....71 5.4 Discussion……………….……………………………………………75 Chapter 6: Discussion and Conclusion………….……………….…………….77 6.1 Discussion…………………..…………………………………………77 6.2 Conclusion…………………………………..……………...………….80 Reference……………………………………………………...…………………….82 | |
dc.language.iso | en | |
dc.title | 正子射影斷層掃描影像研究神經痛和癌症痛之大腦活性改變區域 | zh_TW |
dc.title | FDG-PET study of brain changes in neuropathic and cancer pain | en |
dc.type | Thesis | |
dc.date.schoolyear | 107-2 | |
dc.description.degree | 博士 | |
dc.contributor.coadvisor | 孫維仁 | |
dc.contributor.oralexamcommittee | 許駿,謝仁俊,陳志成,徐百川 | |
dc.subject.keyword | 止痛藥物,腦部葡萄糖代謝,正子射影斷層掃描影像,腦島皮質,疼痛 機制, | zh_TW |
dc.subject.keyword | Analgesics,Brain glucose metabolism,FDG-PET,Insular cortex,Pain mechanism, | en |
dc.relation.page | 92 | |
dc.identifier.doi | 10.6342/NTU201901698 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2019-07-22 | |
dc.contributor.author-college | 生命科學院 | zh_TW |
dc.contributor.author-dept | 生命科學系 | zh_TW |
顯示於系所單位: | 生命科學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-108-1.pdf 目前未授權公開取用 | 13.08 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。